Can Anti-Diarrhea pills tame a promising cancer Drug's side effects?
NCT ID NCT07426822
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This phase II trial tests whether giving preventive medications (loperamide for diarrhea and cetirizine for rash) can reduce common side effects of the cancer drug capivasertib when combined with fulvestrant. About 108 adults with HR+/HER2- metastatic breast cancer will participate. The goal is to improve quality of life and help patients stay on treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Capivasertib, fulvestrant, loperamide, cetirizine
- What this could lead to
- If successful, this could show that simple preventive drugs can make a standard breast cancer treatment much more tolerable, helping patients stay on therapy longer.
- What could go wrong
- This is a small, early-phase trial focused on side effects, not on curing cancer. The preventive strategies may not work as hoped, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.